Combined treatment with anthracyclines (e.g., doxorubicin; Dox) and trastuzumab (Trz), a humanized anti-human epidermal growth factor receptor 2 (HER2; ErbB2) antibody, in patients with HER2-positive cancer is limited by cardiotoxicity, as manifested by contractile dysfunction and arrhythmia. The respective roles of the two agents in the cardiotoxicity of the combined therapy are incompletely understood. To assess cardiac performance, T-tubule organization, electrophysiological changes and intracellular Ca <sup>2+</sup> handling in cardiac myocytes (CMs) using an in vivo rat model of Dox/Trz-related cardiotoxicity. Adult rats received 6 doses of either Dox or Trz, or the two agents sequentially. Dox-mediated left ventricular (LV...
Aim: Trastuzumab can induce cardiotoxicity, particularly when combined with anthracyclines. Myocardi...
Background: The molecular and cellular mechanisms corresponding to the compensatory and maladaptive ...
Doxorubicin is an antineoplastic in the anthracycline class widely used for the treatment of several...
Combined treatment with anthracyclines (e.g., doxorubicin; Dox) and trastuzumab (Trz), a humanized a...
International audienceCardiac failure is a common complication in cancer survivors treated with anth...
Human epidermal growth factor receptor-2 (HER2) is overexpressed in up to 30% of breast cancer cases...
International audienceAnticancer drugs continue to cause significant reductions in left ventricular ...
Trastuzumab, a monoclonal antibody that is selective for cells that overexpress the erbB2 receptor p...
Cancer treatment has advanced considerably in recent years, allowing a reduction in mortality. Longe...
BACKGROUND: Trastuzumab has significantly improved the prognosis of breast cancer patients overexpre...
Aim: Trastuzumab can induce cardiotoxicity, particularly when combined with anthracyclines. Myocardi...
Introduction: The clinical use of anthracyclines, like doxorubicin, is a double-edged sword. On one ...
Aim: Trastuzumab can induce cardiotoxicity, particularly when combined with anthracyclines. Myocardi...
Background: The molecular and cellular mechanisms corresponding to the compensatory and maladaptive ...
Doxorubicin is an antineoplastic in the anthracycline class widely used for the treatment of several...
Combined treatment with anthracyclines (e.g., doxorubicin; Dox) and trastuzumab (Trz), a humanized a...
International audienceCardiac failure is a common complication in cancer survivors treated with anth...
Human epidermal growth factor receptor-2 (HER2) is overexpressed in up to 30% of breast cancer cases...
International audienceAnticancer drugs continue to cause significant reductions in left ventricular ...
Trastuzumab, a monoclonal antibody that is selective for cells that overexpress the erbB2 receptor p...
Cancer treatment has advanced considerably in recent years, allowing a reduction in mortality. Longe...
BACKGROUND: Trastuzumab has significantly improved the prognosis of breast cancer patients overexpre...
Aim: Trastuzumab can induce cardiotoxicity, particularly when combined with anthracyclines. Myocardi...
Introduction: The clinical use of anthracyclines, like doxorubicin, is a double-edged sword. On one ...
Aim: Trastuzumab can induce cardiotoxicity, particularly when combined with anthracyclines. Myocardi...
Background: The molecular and cellular mechanisms corresponding to the compensatory and maladaptive ...
Doxorubicin is an antineoplastic in the anthracycline class widely used for the treatment of several...